Department of Neurosurgery, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Acta Neurochir (Wien). 2022 Feb;164(2):359-372. doi: 10.1007/s00701-021-05044-2. Epub 2021 Dec 2.
Due to rising costs in health care delivery, reimbursement decisions have progressively been based on quality measures. Such quality indicators have been developed for neurosurgical procedures, collectively. We aimed to evaluate their applicability in patients that underwent surgery for vestibular schwannoma and to identify potential new disease-specific quality indicators.
One hundred and three patients operated due to vestibular schwannoma were subject to analysis. The primary outcomes of interest were 30-day and 90-day reoperation, readmission, mortality, nosocomial infection and surgical site infection (SSI) rates, postoperative cerebral spinal fluid (CSF) leak, facial, and hearing function. The secondary aim was the identification of prognostic factors for the mentioned primary outcomes.
Thirty-day (90-days) outcomes in terms of reoperation were 10.7% (14.6%), readmission 9.7% (13.6%), mortality 1% (1%), nosocomial infection 5.8%, and SSI 1% (1%). A 30- versus 90-day outcome in terms of CSF leak were 6.8% vs. 10.7%, new facial nerve palsy 16.5% vs. 6.1%. Hearing impairment from serviceable to non-serviceable hearing was 6.8% at both 30- and 90-day outcome. The degree of tumor extension has a significant impact on reoperation (p < 0.001), infection (p = 0.015), postoperative hemorrhage (p < 0.001), and postoperative hearing loss (p = 0.026).
Our data demonstrate the importance of entity-specific quality measurements being applied even after 30 days. We identified the occurrence of a CSF leak within 90 days postoperatively, new persistent facial nerve palsy still present 90 days postoperatively, and persisting postoperative hearing impairment to non-serviceable hearing as potential new quality measurement variables for patients undergoing surgery for vestibular schwannoma.
由于医疗保健成本的上升,报销决策逐渐基于质量指标。这些质量指标是针对神经外科手术共同制定的。我们旨在评估其在接受前庭神经鞘瘤手术的患者中的适用性,并确定潜在的新的疾病特异性质量指标。
对 103 例因前庭神经鞘瘤而行手术的患者进行分析。主要观察指标为 30 天和 90 天的再次手术、再入院、死亡率、医院感染和手术部位感染(SSI)率、术后脑脊液(CSF)漏、面瘫和听力功能。次要目的是确定上述主要结局的预后因素。
30 天(90 天)的再手术结果为 10.7%(14.6%)、再入院率为 9.7%(13.6%)、死亡率为 1%(1%)、医院感染率为 5.8%、SSI 发生率为 1%(1%)。30 天与 90 天 CSF 漏的结果分别为 6.8%比 10.7%,新面瘫 16.5%比 6.1%。30 天和 90 天的听力从可利用到不可利用的听力损害发生率分别为 6.8%和 6.8%。肿瘤延伸程度对视神经再手术(p<0.001)、感染(p=0.015)、术后出血(p<0.001)和术后听力损失(p=0.026)有显著影响。
我们的数据表明,即使在 30 天后,实体特异性质量测量也很重要。我们发现术后 90 天内发生 CSF 漏,术后 90 天仍存在新的持续性面瘫,术后听力下降至不可用听力,这些都是接受前庭神经鞘瘤手术患者的潜在新的质量测量变量。